How lung cancer's return pattern predicts survival after first treatment fails

When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer grows.
Pharmabiz

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...
Nasdaq

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD ...

– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy ...
BlackDoctor.org

Breakthrough Trials: How AI Immunotherapies Are Accelerating Personalized Cancer Care

Then you have the fact that clinical trials often underrepresent minorities. This can lead to skewed AI models, with 80 percent of trials facing recruitment delays due to these issues. Given that ...
WebMD

Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) - Uses, Side Effects, and More

Overview: Keytruda Qlex is a medicine that is used to treat many types of cancer. This medicine is given to you as an injection under your skin by a health care provider. This medicine can cause side ...